Advertisement
UK markets closed

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • CRUDE OIL

    83.40
    +1.50 (+1.83%)
     

  • GOLD FUTURES

    2,335.70
    -10.70 (-0.46%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • Bitcoin GBP

    53,324.46
    -92.36 (-0.17%)
     

  • CMC Crypto 200

    1,426.91
    +12.15 (+0.86%)
     

  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

GSK sells anaesthetics to Aspen for up to $370 mln

Reuters - UK Focus

LONDON, Sept 12 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) is to sell its portfolio of anaesthetic drugs to South Africa's Aspen Pharmacare for up to 280 million pounds ($372 million) as part of a drive by the British drugmaker to focus on core therapy areas.

The two firms, which have a long history of working together, said on Monday that Aspen would pay 180 million pounds for the products Ultiva, Nimbex, Tracrium, Mivacron and Anectinein, plus up to 100 million pounds in milestone payments.

GSK, which had already sold the U.S (Other OTC: UBGXF - news) . and Canadian rights to the drugs, earned around 35 million pounds from the anaesthetics in the first half of 2016.

Aspen is also acquiring rights to the remaining GSK thrombosis drug portfolio, while the two companies are ending a broader collaboration in sub-Saharan Africa.

ADVERTISEMENT

The South African group bought most of the thrombosis drug rights in 2013, but GSK had retained certain territories, including China, India and Pakistan.

($1 = 0.7532 pounds) (Reporting by Ben Hirschler; Editing by Alexander Smith)